HI
NVO

Human Investing’s Novo Nordisk NVO Stock Holding History

Human Investing’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763K Sell
15,921
-481
-3% -$20.7K 0.1% 52
2026
Q1 		$603K Sell
16,402
-1,389
-8% -$65.8K 0.09% 58
2025
Q4 		$905K Sell
17,791
-1,019
-5% -$52.1K 0.13% 46
2025
Q3 		$1.04M Sell
18,810
-1,712
-8% -$100K 0.15% 37
2025
Q2 		$1.42M Sell
20,522
-1,376
-6% -$93.6K 0.22% 33
2025
Q1 		$1.52M Sell
21,898
-108
-0.5% -$8.92K 0.27% 32
2024
Q4 		$1.89M Sell
22,006
-867
-4% -$93.8K 0.34% 28
2024
Q3 		$2.72M Sell
22,873
-417
-2% -$55.6K 0.49% 26
2024
Q2 		$3.32M Hold
23,290
– – 0.65% 22
2024
Q1 		$2.99M Sell
23,290
-206
-0.9% -$24.5K 0.6% 26
2023
Q4 		$2.43M Sell
23,496
-1,702
-7% -$168K 0.52% 26
2023
Q3 		$2.29M Sell
25,198
-334
-1% -$29.4K 0.53% 25
2023
Q2 		$2.07M Sell
25,532
-732
-3% -$59.8K 0.47% 27
2023
Q1 		$2.09M Sell
26,264
-1,360
-5% -$96.4K 0.51% 26
2022
Q4 		$1.87M Sell
27,624
-3,500
-11% -$205K 0.48% 28
2022
Q3 		$1.55M Sell
31,124
-408
-1% -$21.9K 0.4% 36
2022
Q2 		$1.76M Sell
31,532
-376
-1% -$20.9K 0.42% 35
2022
Q1 		$1.77M Sell
31,908
-12,500
-28% -$642K 0.39% 37
2021
Q4 		$2.49M Sell
44,408
-11,660
-21% -$632K 0.59% 26
2021
Q3 		$2.69M Sell
56,068
-3,308
-6% -$160K 0.63% 24
2021
Q2 		$2.49M Sell
59,376
-642
-1% -$24.9K 0.61% 27
2021
Q1 		$2.02M Sell
60,018
-6,254
-9% -$223K 0.52% 31
2020
Q4 		$2.31M Sell
66,272
-14,942
-18% -$516K 0.66% 25
2020
Q3 		$2.82M Sell
81,214
-7,342
-8% -$245K 0.93% 19
2020
Q2 		$2.9M Sell
88,556
-24,702
-22% -$788K 1.02% 15
2020
Q1 		$3.41M Sell
113,258
-11,704
-9% -$348K 1.48% 12
2019
Q4 		$3.62M Buy
124,962
+36
+0% +$997 1.18% 13
2019
Q3 		$3.23M Sell
124,926
-2,004
-2% -$50.7K 1.14% 14
2019
Q2 		$3.24M Sell
126,930
-5,964
-4% -$147K 1.18% 15
2019
Q1 		$3.48M Sell
132,894
-3,456
-3% -$84.9K 1.3% 12
2018
Q4 		$3.14M Buy
+136,350
New +$3.03M 1.31% 10

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Human Investing's NVO Position: Q2 2026 in Review

Human Investing reduced its Novo Nordisk (NVO) stake by 2.9% in Q2 2026, selling an estimated $20.7K and leaving 15,921 shares worth $763K. The position accounts for 0.1% of the portfolio, ranked #52.

Human Investing first reported a position in NVO in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.62M in Q4 2019. 583 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Human Investing held 15,921 shares of Novo Nordisk worth $763K as of Q2 2026.
  • Human Investing sold 481 Novo Nordisk shares in Q2 2026, an estimated $20.7K.
  • Novo Nordisk made up 0.1% of Human Investing's portfolio in Q2 2026, its #52 holding.
  • Human Investing first reported a position in Novo Nordisk in Q4 2018 and has held it in 31 quarters since.
  • Human Investing's Novo Nordisk position peaked at $3.62M in Q4 2019.
  • 583 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Human Investing's 13F filing for Q2 2026, filed 20 Jul 2026.